Halozyme Therapeutics (HALO) Other financing activities (2020 - 2022)

Halozyme Therapeutics (HALO) has 3 years of Other financing activities data on file, last reported at $639000.0 in Q4 2022.

• Other financing activities for Q4 2022 came in at $639000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2023 was $6.6 million (changed 0.0% YoY), and the FY2025 annual result was $4.9 million, changed N/A from the prior year.
• Other financing activities slipped to $639000.0 in Q4 2022 per HALO's latest filing, from $6.0 million in the prior quarter.
• Over five years, Other financing activities peaked at $6.0 million in Q2 2022 and troughed at -$68000.0 in Q2 2020.
• A 3-year average of $1.2 million and a median of $234000.0 in 2020 frame the typical range for Other financing activities.
• The sharpest annual moves came in 2021 and 2022: Other financing activities soared 135.29% in 2021, then surged 24912.5% in 2022.
• A 3-year view of Other financing activities shows it stood at -$68000.0 in 2020, then soared by 135.29% to $24000.0 in 2021, then soared by 2562.5% to $639000.0 in 2022.
• Business Quant data shows HALO's Other financing activities at $639000.0 in Q4 2022, $6.0 million in Q2 2022, and $24000.0 in Q2 2021.